Technology ID
TAB-2601
Use of Vitronectin as a Biomarker for the Detection of Dengue Hemorrhagic Fever
E-Numbers
E-147-2013-0
Lead Inventor
Hunsperger, Elizabeth (CDC)
Co-Inventors
Ndao, Momar (McGill University)
Tomashek, Kay (CDC)
Poole-Smith, Betty (CDC)
Applications
Diagnostics
Therapeutic Areas
Infectious Disease
Development Status
- Pre-clinical
- In vitro data available
Lead IC
CDC
ICs
CDC
Dengue hemorrhagic fever (DHF) is a severe, potentially deadly infection spread by mosquitos. CDC scientists have identified vitronectin as an important biomarker of DHF. They have shown vitronectin is significantly reduced in DHF and severe dengue infections when compared to dengue non-hemorrhagic fever patients. Presently, DHF is established by assessing antibody concentrations and other rule-of-thumb criteria, but often these assays can be difficult to interpret and lead to false conclusions. Establishing vitronectin levels provides a specific, novel biomarker for DHF, leading to increased accuracy in clinical diagnoses and improved patient outcomes.
Commercial Applications
- Diagnostic biomarker of DHF
- Point-of-care diagnostic testing
- Enzyme-linked immunosorbent assay (ELISA) for clinical and laboratory use
Competitive Advantages
- While there are commercially-available ELISAs to detect vitronectin, these products have not been used for dengue diagnosis
- Vitronectin assessment assays provide a novel, specific biomarker for the DHF disease state
- Easily developed for serologic diagnostic assays
Licensing Contact: